BACKGROUND: Treatment eligibility rates in patients with HCV monoinfection have not been directly compared with patients with HCV/HIV coinfection. These data are important for planning interventions to optimize HCV management. METHOD: We enrolled consecutive HCV-monoinfected and HCV/HIV-coinfected subjects presenting to hepatology and HIV clinics at three academic medical centers. Data were obtained through structured subject and provider interviews and a review of medical records. RESULTS: Of the 399 subjects enrolled, 241 (60%) were HCV monoinfected and 158 (40%) were HCV/HIV coinfected. HCV/HIV-coinfected subjects were less likely to have indications for treatment based on HCV RNA positivity (70.9% vs. 81.3%, p = .04) but were more likely to have at least one contraindication to treatment (81.6% vs. 64.9%, p < .004). Depression and ongoing alcohol and injection drug abuse were more common in the HCV/HIV-coinfected persons. HCV/HIV-coinfected persons were less likely to undergo liver biopsy or to ever get treatment for HCV. CONCLUSIONS: HCV/HIV-coinfected persons are less likely to undergo a liver biopsy or be eligible for HCV therapy and are more likely to have treatment contraindications compared with HCV-monoinfected subjects. Strategies to address modifiable factors (e.g., depression, substance abuse) may enhance treatment eligibility in HCV-infected populations.
BACKGROUND: Treatment eligibility rates in patients with HCV monoinfection have not been directly compared with patients with HCV/HIV coinfection. These data are important for planning interventions to optimize HCV management. METHOD: We enrolled consecutive HCV-monoinfected and HCV/HIV-coinfected subjects presenting to hepatology and HIV clinics at three academic medical centers. Data were obtained through structured subject and provider interviews and a review of medical records. RESULTS: Of the 399 subjects enrolled, 241 (60%) were HCV monoinfected and 158 (40%) were HCV/HIV coinfected. HCV/HIV-coinfected subjects were less likely to have indications for treatment based on HCV RNA positivity (70.9% vs. 81.3%, p = .04) but were more likely to have at least one contraindication to treatment (81.6% vs. 64.9%, p < .004). Depression and ongoing alcohol and injection drug abuse were more common in the HCV/HIV-coinfectedpersons. HCV/HIV-coinfectedpersons were less likely to undergo liver biopsy or to ever get treatment for HCV. CONCLUSIONS:HCV/HIV-coinfectedpersons are less likely to undergo a liver biopsy or be eligible for HCV therapy and are more likely to have treatment contraindications compared with HCV-monoinfected subjects. Strategies to address modifiable factors (e.g., depression, substance abuse) may enhance treatment eligibility in HCV-infected populations.
Authors: S Zeuzem; S V Feinman; J Rasenack; E J Heathcote; M Y Lai; E Gane; J O'Grady; J Reichen; M Diago; A Lin; J Hoffman; M J Brunda Journal: N Engl J Med Date: 2000-12-07 Impact factor: 91.245
Authors: G W McCaughan; M Omata; D Amarapurkar; S Bowden; W C Chow; A Chutaputti; G Dore; E Gane; R Guan; S S Hamid; W Hardikar; C K Hui; W Jafri; J-D Jia; M-Y Lai; L Wei; N Leung; T Piratvisuth; S Sarin; J Sollano; R Tateishi Journal: J Gastroenterol Hepatol Date: 2007-05 Impact factor: 4.029
Authors: Shawn L Fultz; Amy C Justice; Adeel A Butt; Linda Rabeneck; Sharon Weissman; Maria Rodriguez-Barradas Journal: Clin Infect Dis Date: 2003-04-01 Impact factor: 9.079
Authors: Adeel A Butt; Amy C Justice; Melissa Skanderson; Michael O Rigsby; Chester B Good; C Kent Kwoh Journal: Gut Date: 2006-09-27 Impact factor: 23.059
Authors: H Zylberberg; Y Benhamou; J L Lagneaux; A Landau; M L Chaix; H Fontaine; M Bochet; T Poynard; C Katlama; G Pialoux; C Bréchot; S Pol Journal: Gut Date: 2000-11 Impact factor: 23.059
Authors: Jason Grebely; Krista A Genoway; Jesse D Raffa; Gurbir Dhadwal; Tasleem Rajan; Grey Showler; Kate Kalousek; Fiona Duncan; Mark W Tyndall; Chris Fraser; Brian Conway; Benedikt Fischer Journal: Drug Alcohol Depend Date: 2007-11-09 Impact factor: 4.492
Authors: Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu Journal: N Engl J Med Date: 2002-09-26 Impact factor: 91.245
Authors: Lynn E Taylor; Sarah E Bowman; Stacey Chapman; Nickolas Zaller; Michael D Stein; Patricia A Cioe; Michaela A Maynard; Barbara Hedgis McGovern Journal: Drug Alcohol Depend Date: 2010-12-21 Impact factor: 4.492
Authors: Adeel A Butt; Peng Yan; Vincent Lo Re; David Rimland; Matthew B Goetz; David Leaf; Matthew S Freiberg; Marina B Klein; Amy C Justice; Kenneth E Sherman Journal: JAMA Intern Med Date: 2015-02 Impact factor: 21.873
Authors: Lars Peters; Amanda Mocroft; Vincent Soriano; Jürgen Rockstroh; Andri Rauch; Anders Karlsson; Brygida Knysz; Christian Pradier; Kai Zilmer; Jens D Lundgren Journal: PLoS One Date: 2013-05-27 Impact factor: 3.240